The multifaceted roles of NLRP3-modulating proteins in virus infection

James Harris1,2* and Natalie A. Borg3,4*

1Cell Biology Assays Team, Biomedical Manufacturing, Commonwealth Scientific and Industrial Research Organisation (CSIRO), Clayton, VIC, Australia, 2Centre for Inflammatory diseases, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia, 3Immunity and Immune Evasion Laboratory, Chronic Infectious and Inflammatory Diseases Research, School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, Australia, 4Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, Australia

The innate immune response to viruses is critical for the correct establishment of protective adaptive immunity. Amongst the many pathways involved, the NLRP3 [nucleotide-binding oligomerisation domain (NOD)-like receptor protein 3 (NLRP3)] inflammasome has received considerable attention, particularly in the context of immunity and pathogenesis during infection with influenza A (IAV) and SARS-CoV-2, the causative agent of COVID-19. Activation of the NLRP3 inflammasome results in the secretion of the proinflammatory cytokines IL-1β and IL-18, commonly coupled with pyroptotic cell death. While this mechanism is protective and key to host defense, aberrant NLRP3 inflammasome activation causes a hyperinflammatory response and excessive release of cytokines, both locally and systemically. Here, we discuss key molecules in the NLRP3 pathway that have also been shown to have significant roles in innate and adaptive immunity to viruses, including DEAD box helicase X-linked (DDX3X), vimentin and macrophage migration inhibitory factor (MIF). We also discuss the clinical opportunities to suppress NLRP3-mediated inflammation and reduce disease severity.

KEYWORDS
NLRP3, inflammasome, influenza, COVID-19, DDX3X, MIF, vimentin

Entry of SARS-CoV-2 and influenza virus into the host cell

SARS-CoV-2 and influenza A virus (IAV) infections have caused two major pandemics in the past century, resulting in millions of deaths. SARS-CoV-2 is an enveloped virus with a single stranded positive sense RNA genome of approximately 30,000 nucleotides. The SARS-CoV-2 genome encodes 4 structural proteins (spike,
envelope, membrane, nucleocapsid), 16 non-structural proteins (nsp1-16) and multiple accessory proteins that together have proven masterful at entering host cells and manipulating host machinery to replicate their genome. The SARS-CoV-2 spike protein studs the viral envelope and facilitates entry into host cells with the help of several host cellular proteases, including furin and type II transmembrane serine protease (TMPRSS2) (1–3). These host proteases cleave the spike protein into its two subunits; the S1 domain, which interacts with the angiotensin converting enzyme 2 (ACE2) receptor on the host cell surface, and the S2 domain which mediates virus-host cell membrane fusion (4). Besides ACE2, SARS-CoV-2 engages with alternate entry receptors including heparan sulfate (5), cluster of differentiation 147 (CD-147) (6), neuropilin-1 (7) and the C-type lectin receptors DC-SIGN (8, 9), L-SIGN (10) and sialic acid binding Ig like lectin 1 (SIGLEC1) (11). Together, these enable the release of SARS-CoV-2 genomic RNA into the host cell cytoplasm and/or induction of the innate immune response. IAV, on the other hand, is a negative stranded RNA virus with a genome approximately half that of SARS-CoV-2 that encodes 10 essential proteins, including matrix proteins 1 and 2 (M1 and M2), three RNA polymerases, nucleoprotein (NP), non-structural proteins 1 (NS1) and 2 (NS2) and the surface antigens haemagglutinin (HA) and neuraminidase (NA) (12). The HA protein mediates viral entry by preferentially binding to α2,6-linked sialic acid receptors, typically on the surface of host epithelial cells, and enters the cell by receptor-mediated endocytosis (13). Upon entry of IAV and SARS-CoV-2, the host translational machinery is hijacked to replicate viral RNA and transcribe viral proteins required for the release of mature virions from the host cell and to subvert immune defenses. Thus, the clinical outcome of viral infection is a battle between viral pathogenesis and the host immune response to infection.

Innate immune response to viral infection

The innate immune system detects and responds to infectious agents to provide rapid frontline defense. This frontline defense is achieved using immune sentinels, or pattern recognition receptors (PRRs), that recognize exogenous pattern-associated molecular patterns (PAMPs) and endogenous damage-associated molecular patterns (DAMPs). In the case of viral infection, PAMPs may be associated with the viral particle, such as the SARS-CoV-2 spike protein which induces inflammation via the C-type lectin receptors (14) or toll-like receptor (TLR) 2 (15), or intermediates of viral replication, such as SARS-CoV-2 double-stranded RNA which activates the retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) or TLRs (16, 17) (Figure 1). Virus-induced cell lysis can also lead to the release of host products or DAMPs, that similarly initiate innate immune responses. As a result, viral infection can trigger multiple signaling cascades leading to the release of multiple cytokines, including the IL-1 family cytokines IL-1β and IL-18, and type I and type III interferons (IFNs) (Figure 1). Type I IFNs, such as IFN-α and IFN-β, signal through the type I IFN receptor (IFNAR) complex, whereas type III IFNs, termed IFN-λs, signal via the IFN lambda receptor 1 (IFNLRL1) and interleukin-10 receptor 2 (IL-10R2) complex (18). The engagement of IFNs with their cognate receptors activates the receptor-associated protein tyrosine kinases Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2), which phosphorylate signal transducer and activator of transcription 1 (STAT1) and STAT2 (19). The dimerization and nuclear translocation of STAT1 and STAT2 leads to the activation of hundreds of interferon-stimulated genes (ISGs) to restrict viral replication and limit viral spread (Figure 1). IL-1 family cytokines are potent pro-inflammatory and pyrogenic immunomodulators whose release in response to virus replication activates multiple immune genes and recruits immune cells to the site of infection. The processing and release of both IL-1β and IL-18 is typically dependent on the activation of an inflammasome, in the case of viruses most commonly the absent in melanoma 2 (AIM2) and/or nucleotide-binding oligomerization domain (NOD)-like receptor protein 3 (NLRP3) inflammasome (20).

The NLRP3 inflammasome

NLRP3 is a cytoplasmic PRR that is mainly expressed in monocytes and macrophages. It consists of an N-terminal pyrin domain followed by a central NACHT [NAIP (neuronal apoptosis inhibitor protein), CIITA (MHC class II transcription activator), HET-E (heterokaryon incompatibility), TP1 (telomerase-associated protein 1)] domain and C-terminal leucine-rich-repeats (LRRs) (21). NLRP3 is normally maintained in an autoinhibited state (22), however, it is activated upon sensing diverse stress signals and signatures of infection, leading to the assembly of the NLRP3 inflammasome, which can elicit both inflammatory and antiviral responses. Canonical activation of the NLRP3 inflammasome generally requires a priming and then activation step (23), although NLRP3 inflammasomes may also be formed in the absence of priming (24). The priming signal, which can be initiated by various PAMPs and DAMPs, activates nuclear factor-κB (NF-κB), which upregulates the expression of pro-IL-1β, pro-IL-18 and NLRP3, thus priming NLRP3 for inflammasome formation. The second activating signal again stems from diverse inducers/indicators of stress (e.g., pore forming toxins such as nigericin), however, all have been reported to induce potassium (K+) efflux, suggesting that this is a unifying process required for inflammasome assembly (25). The activating signal elicits a change in NLRP3 conformation

Harris and Borg 10.3389/fimmu.2022.987453

Frontiers in Immunology

02

frontiersin.org
that allows it to oligomerize and recruit ASC (apoptosis-associated speck-like protein containing a CARD) via a pyrin-pyrin domain interaction. ASC in turn, recruits pro-caspase 1 via a CARD-CARD interaction, together forming an assembled NLRP3 inflammasome (Figure 1). Within this assembled inflammasome, pro-caspase-1 undergoes autocatalytic activation and cleaves pro-IL-1β, pro-IL-18 and the pore forming protein gasdermin D, which prompts gasdermin D to oligomerize and form pores in the cell membrane (26–29). These pores allow release of the mature and active pro-inflammatory cytokines IL-1β and IL-18, which is commonly coupled with cell death via pyroptosis (30) (Figure 1). This process destroys infected cells, which in the case of viral infection prevents them from fueling further replication, and releases the cell contents, allowing further amplification of the innate immune response.

Multiple RNA viruses, and some DNA viruses, are sensed by, and activate, the NLRP3 inflammasome but precisely how is not completely understood. Priming is most likely through activation of TLR3 and/or TLR7, which recognize nucleic acids. Activation of NLRP3, on the other hand, may occur through multiple mechanisms. Some viruses, including vesicular stomatitis virus (VSV) and encephalomyocarditis virus (EMCV) may activate NLRP3 by increasing K+ efflux as a result of lytic cell death (31). Alternatively, NLRP3 may recognize, directly or indirectly, viral nucleic acids (32) and/or proteins, including the IAV M2 ion channel and/or PB1-F2 peptide aggregates (33, 34) and SARS-CoV-2 nucleocapsid protein, nsp6 and spike protein (35, 36). Both IAV and SARS-CoV-2 are also able to suppress NLRP3 inflammasome activation via their non-structural protein 1 (NS1) and envelope proteins, respectively. Interestingly, the IAV protein PB1-F2, while an activator as an aggregate, can also inhibit NLRP3 following translocation into the mitochondria (37, 38).

New players in NLRP3 inflammasome activation

Although it is well-established that the NLRP3 inflammasome is a multi-protein complex that requires assembly for its activation, the events leading up to, and regulating, NLRP3 inflammasome activation are unclear. Identifying new players that regulate NLRP3 inflammasome activation furthers our understanding of this critical process and reveals new ways to block aberrant activation which occurs in several disease states, including severe SARS-CoV-2 and IAV infection. While new proteins undoubtedly remain to be discovered, recent studies have highlighted critical roles for
three proteins in NLRP3 inflammasome activation and assembly. DEAD-box helicase 3X (DDX3X), vimentin and macrophage migration inhibitory factor (MIF).

**DEAD-box helicase 3X**

The family of DEAD box helicase proteins, including DDX3X, are comprised of ATP-dependent RNA helicases that unwind RNA or remodel protein-RNA complexes. As a result, they are involved in almost all stages of RNA metabolism in eukaryotic cells, including transcription, splicing, nuclear export and mRNA translation. DDX3X, which is encoded on the X-chromosome, has a role to play in multiple biological functions including innate immunity and the cellular stress response. We and others have previously shown that DDX3X plays a prominent role in enhancing the RLR-mediated type I interferon (IFN) antiviral response by associating with various RLR signaling molecules including TBK1 (TANK-binding kinase 1) and IKKε (I-kappa-B kinase-e) and direct interaction with the IFNB1 promoter (39–43) (Figure 1). DDX3X also participates in the formation of cytoplasmic stress granules, membraneless cytosolic bodies that form during the cell stress response, as well as during viral infection (44, 45). Stress granules are highly dynamic structures that form when translation initiation is stalled and they contain a diverse proteome of RNA-binding and other proteins, along with untranslated mRNAs (46, 47). The biological functions of stress granules are not well understood, but by sequestering specific cytosolic constituents, they modulate multiple signaling pathways, including mechanistic target of rapamycin (mTOR), receptor for activated C kinase 1 (RACK1) and tumor necrosis factor (TNF) receptor-associated factor 2 (TRAF2) (47). DDX3X dysfunction is associated with a wide range of diseases, including cancer, inflammation, female intellectual disability and viral infections (48–50). DDX3X has a homologue encoded on the Y-chromosome known as DDX3Y. With 92% sequence identity, DDX3X and DDX3Y have functionally redundant roles in translation (51). Despite this, Szapansos et al. recently showed that male and female mice lacking DDX3X in the hematopoietic system differ in their susceptibility to the intracellular bacterial pathogen, *Listeria monocytogenes* (52). This is attributed to the distinct expression profiles of DDX3X versus DDX3Y, with immune cells exhibiting differential sex biased *DDX3X/DDX3Y* gene expression (52, 53).

**DDX3X and NLRP3**

DDX3X has been attributed a role in NLRP3 inflammasome activation as cultured cell lines deficient in Ddx3x (54, 55) and bone marrow derived macrophages (BMDMs) that lack DDX3X demonstrated impaired release of IL-1β and IL-18 (55). Based on co-immunoprecipitation analysis, it is proposed that DDX3X binds the central NACHT domain of NLRP3 to facilitate NLRP3 oligomerization and inflammasome assembly, both of which are key to NLRP3 inflammasome activation. However, a direct interaction between NLRP3 and DDX3X has not yet been confirmed using recombinant proteins.

Intriguingly, two independent studies have linked stress granule assembly with inhibition of NLRP3 inflammasome activation in response to various cellular stressors, including viral infection (35, 36). Further, BMDMs derived from mice that lacked DDX3X in the myeloid compartment were used to establish DDX3X as a pivotal link between these two mutually exclusive cellular responses to stress. Notably, when DDX3X is incorporated into stress granules it is no longer available to partake in NLRP3 inflammasome activation, thus favoring cell survival (Figure 1) (55). Therefore, DDX3X availability influences cell-fate decisions in stressed cells.

DDX3X also binds NLRP11, another member of the NOD-like receptor family, but unlike NLRP3 NLRP11 does not form a classical inflammasome and early studies on its function suggest roles in regulating NF-κB and type I IFN (57–59). Further, and as per stress granule formation, NLRP11 has been shown to inhibit NLRP3 inflammasome activation, a phenomenon again attributed to DDX3X sequestration, this time by NLRP11. Perplexingly, NLRP11 was later identified as an essential component required for NLRP3 inflammasome activation (60). How NLRP11 differentiates between its inhibitory and activating effects on NLRP3 inflammasome activation is currently unclear, however it is possible that DDX3X influences this process. Despite the conserved architecture of NLRP3 and NLRP11, DDX3X binds the LRR domain of NLRP11 as opposed to the NACHT domain of NLRP3. DDX3X might therefore concomitantly bind both NLRP3 and NLRP11, a concept that should be further investigated.

**DDX3X and immunity to viruses**

DDX3X plays multiple roles in host antiviral defense following the detection of viral RNA, and binds to, or is bound by, numerous viral proteins from diverse virus families, the outcomes of which determine whether DDX3X plays a pro- or antiviral role in infection. DDX3X plays antiviral roles in vaccinia virus and IAV infection. As such, vaccinia virus and IAV encode proteins to counteract DDX3X. The K7 protein binds to DDX3X to block IFN-β production (61) (Table 1). During IAV infection DDX3X regulates stress granule formation, the type I IFN response and NLRP3 inflammasome activation (Table 1) (56, 71). On the other hand, the IAV NS1 protein, which interacts with DDX3X in an RNA-independent manner, inhibits both stress-granule formation and the type I IFN response, however whether NS1 promotes or inhibits NLRP3 inflammasome activation is contentious (39, 56, 71–75). Despite the influence of NS1, DDX3X protects IAV-infected
### TABLE 1 DDX3X, vimentin and MIF are host proteins with roles in antiviral activity and NLRP3 activation.

| NLRP3 inflammasome mediator | Virus | Role in infection | References |
|-----------------------------|-------|------------------|------------|
| *DDX3X*                     | Human immunodeficiency virus type I | DDX3X is required for nuclear export of incompletely spliced human immunodeficiency virus type I RNA transcripts. | (62, 63) |
|                             | SARS-CoV-2 | DDX3X inhibitors suppress human immunodeficiency virus type I replication. | (64–68) |
|                             | DDX3X catalytic inhibitor RK-33 suppresses viral load in Calu-3 cells. | | (69) |
|                             | DDX3X interacts with SARS-CoV-2 nucleoprotein in infected Vero cells and may subvert stress granule machinery. | | (70) |
| Influenza A virus           | DDX3X plays a role in NLRP3 inflammasome activation, stress granule assembly and production of type I interferon; stress granule assembly and type I interferon production is blocked by influenza virus NS1 protein, whereas its effect on NLRP3 is contentious. | | (39, 56, 71–75) |
| Respiratory syncytial virus | DDX3X binds to respiratory syncytial virus M2 mRNA to initiate translation which enables the onset of genome replication. | | (76) |
| Dengue virus                | DDX3X catalytic inhibitor RK-33 suppresses viral load in Calu-3 cells. | | (77) |
| DDX3X binds dengue virus capsid and NS5 proteins, but knockdown showed differential effects on virus production. | | (78, 79) |
| Vaccinia virus              | DDX3X is required for IFN-β release and inhibits virus replication in HEK-293 cells. | | (82) |
| Zika virus                  | Vaccinia virus K3 protein forms a complex with DDX3X and inhibits IFN-β. | | (61) |
| West Nile virus            | DDX3X directly binds and unwinds *in vitro* transcribed Zika virus 5' terminal regions. | | (83) |
| DDX3X catalytic inhibitor RK-33 suppresses viral load in Vero cells. | | (77) |
| Human paramyxovirus type 3 | DDX3X inhibitors suppress dengue virus infection in Huh-7 and Vero cells. | | (77, 80, 81) |
| Hepatitis B virus           | DDX3X is required for IFN-β release and inhibits virus replication in HEK-293 cells. | | (82) |
| Hepatitis C virus           | DDX3X binds hepatitis C virus 3' untranslated regions and facilitates viral assembly/infection. | | (89–92) |
| Japanese encephalitis virus | DDX3X interacts with hepatitis C virus core protein, but the importance for replication is contentious. | | (89–91, 93–97) |
| Vimentin                    | DDX3X binds and unwinds Japanese encephalitis virus 3' and/or 5' untranslated regions and positively regulates viral protein expression. | | (83, 86) |
| Human immunodeficiency virus type 1 | DDX3X enhances viral load in Vero cells. | | (77) |
| SARS-CoV/SARS-CoV-2         | DDX3X binds hepatitis B virus polymerase and inhibits hepatitis B virus reverse transcription following nucleocapsid assembly. | | (87) |
| Vimentin interacts with the SARS-CoV spike protein, possible role in virus entry in Vero cells. | | (99) |
| Vimentin interacts with SARS-CoV-2 spike protein and facilitates virus entry via ACE2 in HEK-293 cells. | | (100) |
| Vimentin, ACE2 and SARS-CoV-2 co-localize in structures consistent with primary cilia in multiple cell types. | | (101) |
| Vimentin-targeting compound ALD-R491 reduced ACE2-mediated infection of lentivirus pseudotyped with SARS-CoV-2 spike protein in HEK-293 cells, increased anti-microbial activity of macrophages, activates T regulatory cells and had therapeutic efficacy in a mouse adapted model of SARS-CoV-2 infection. | | (102) |
| Influenza A virus           | Influenza A infection is reduced in *Vim*−/− mouse embryonic fibroblasts. | | (103) |
| Vimentin affects the distribution of endosomes and their acidification during influenza A virus infection impairing viral genome release from endosomes. | | (103) |
| Vimentin interacts with the PB2 subunit of the influenza A virus polymerase to enhance its activity and virus replication. | | (104) |
| Dengue virus                | Viral load is increased in *Vim*−/− human brain microvascular endothelial cells and *Vim*−/− SV129 sucking mice infected with Dengue virus had increased viral load and more severe brain damage. | | (105) |
| Vimentin interacts with NS4A in Huh-7 cells to facilitate viral replication. | | (106) |
| Vaccinia virus              | Intracellular vimentin is found around viral factories in HeLa cells and within viroplasm foci, where virus assembly occurs. | | (107) |

(Continued)
mice against severe lung pathology and viral spread, thus aiding their survival (Table 1) (56).

Although many viruses inhibit stress granules, several viruses interact with stress granule components to fulfill their replication cycle. Hepatitis C virus (HCV) infection induces an interaction between DDX3X and the HCV 3’ untranslated region which prompts DDX3X and IKKβ to associate with stress granules (89, 90). These in turn bind to HCV protein and RNA elements to form the HCV replication complex (Table 1). Intriguingly, siRNA knockdown of DDX3X or key stress granule proteins revealed a beneficial role for DDX3X and stress granules in HCV infection (90–92). This role may serve to prolong cell survival and favor persistent HCV infection (133). DDX3X also binds to the HCV core protein which associates with lipid droplets essential for infectious HCV production, however the role of this interaction in infection is contentious (89–91, 93–97).

In addition to HCV replication, DDX3X promotes the replication of many other viruses as exemplified by DDX3X knockdown/knockout severely limiting human immunodeficiency virus type 1 (HIV-1) (62, 63), hepatitis B (HBV) (88), Japanese encephalitis virus (JEV) (86) and SARS-CoV-2 (70) infectious virus production. Further, we and others have also shown that inhibitors that suppress DDX3X activity in vitro can limit infectious virus production by HCV (80), respiratory syncytial virus (RSV) (76, 77), West Nile virus (WNV) (77, 80, 85), Zika virus (77), SARS-CoV-2 (70), HIV-1 (64–67) and drug-resistant HIV-1 (68). Therefore, for these many viruses, DDX3X plays a pro-viral role in replication. On the other hand, it is worth noting that both pro- and anti-viral roles have been attributed to DDX3X in dengue virus (DENV) (77, 80, 85), Zika virus (77), SARS-CoV-2 (70) infectious virus production. Further, we and others have also shown that inhibitors that suppress DDX3X activity in vitro can limit infectious virus production by HCV (80), respiratory syncytial virus (RSV) (76, 77), West Nile virus (WNV) (77, 80, 85), Zika virus (77), SARS-CoV-2 (70), HIV-1 (64–67) and drug-resistant HIV-1 (68). Therefore, for these many viruses, DDX3X plays a pro-viral role in replication. On the other hand, it is worth noting that both pro- and anti-viral roles have been attributed to DDX3X in dengue virus (DENV) infection. While DDX3X inhibitors and knockdown suppress the replication of DENV or a DENV replicon (77, 78, 80), Kumar and colleagues (79) showed that DDX3X knockdown led to an increase in DENV viral titer and conversely DDX3X overexpression inhibited DENV replication. Likewise, DDX3X was shown to suppress DENV infection by activating IFN (82). Thus, DDX3X may have contrasting roles to play in the biology

### Table 1

| NLRP3 inflammasome mediator | Virus | Role in infection | References |
|----------------------------|-------|-------------------|------------|
| Cytomegalovirus             | Loss/disruption of vimentin in cells reduced viral entry and slowed intracellular capsid transport. | (108) |
| Human Enterovirus           | Vimentin regulates the synthesis of human enterovirus non-structural proteins 2A, 3C, and 3D which regulate host cell processes, including prolonged cell survival. | (109) |
| Human papillomavirus        | Cell surface expressed vimentin restricts binding to cell surface receptor and internalization into pgsD677, HaGaT, HeLa, and NIKS cells. | (110) |
| Hepatitis C virus           | Vimentin binds the hepatitis C core protein and influences its proteasomal-mediated degradation to impact virus replication in Huh-7 cells. | (111) |
| Foot and mouth disease virus| Intracellular vimentin interacts with virus non-structural Protein 3A (NS3A) in foetal bovine kidney cells and hinder viral replication in PK-15 cells. | (112) |
| MIF                        | Plasma MIF is increased in patients with human immunodeficiency virus type I and is released in greater amounts by infected PBMC. MIF increases viral replication of CCR5- and CXCR4-trophic isolates, while anti-MIF antibody inhibits human immunodeficiency virus type I replication in PBMC. | (113) |
| SARS-CoV-2                  | MIF is increased in patients with mild and severe SARS-CoV-2 and may be associated with impaired organ function and increased pulmonary arterial hypertension. | (114–116) |
| Influenza A virus           | MIF is involved in influenza virus replication, contributes to an overactive inflammatory cytokine response and aggravated disease. | (117) |
|                             | Antisense oligodeoxyribonucleotide targeting MIF inhibits propagation of influenza virus (H1N1) in A549 cells. | (118) |
|                             | MIF interacts with influenza virus protein PB1-F2 protein. | (119) |
|                             | MIF is released from necrotic lung epithelial cells infected with influenza virus. | (120) |
| Respiratory syncytial virus | Respiratory syncytial virus infection increases Mif mRNA expression in mouse macrophages and inhibition of MIF with ISO-1 (small molecule inhibitor) inhibits RSV-induced release of TNF, MCP-1 and IL-10. | (121) |
| Dengue virus                | MIF inhibits migration of dengue virus-infected macrophages to limit virus spread but is also involved in pathogenesis of dengue virus infection, including an overactive inflammatory cytokine response, viral replication, vascular permeability and leakage. | (122–128) |
| Zika virus                  | MIF inhibits migration of Zika virus-infected macrophages to limit virus spread; Zika virus blocks NF-κB signaling to reduce MIF expression and its role in inhibiting macrophage migration. | (129) |
| West Nile virus             | MIF facilitates West Nile virus neuroinvasion and replication and causes an overactive inflammatory response. | (130–132) |

| Virus | References |
|-------|------------|
| Vimentin increases viral replication of DENV or a DENV replicon (77, 78, 80), Kumar and colleagues (79) showed that DDX3X knockdown led to an increase in DENV viral titer and conversely DDX3X overexpression inhibited DENV replication. Likewise, DDX3X was shown to suppress DENV infection by activating IFN (82). Thus, DDX3X may have contrasting roles to play in the biology of viral pathogenesis. | (116) |

| Virus | References |
|-------|------------|
| Human immunodeficiency virus type I | Plasma MIF is increased in patients with human immunodeficiency virus type I and is released in greater amounts by infected PBMC. MIF increases viral replication of CCR5- and CXCR4-trophic isolates, while anti-MIF antibody inhibits human immunodeficiency virus type I replication in PBMC. | (113) |
| SARS-CoV-2 | MIF is increased in patients with mild and severe SARS-CoV-2 and may be associated with impaired organ function and increased pulmonary arterial hypertension. | (114–116) |
| Influenza A virus | MIF is involved in influenza virus replication, contributes to an overactive inflammatory cytokine response and aggravated disease. | (117) |
|                             | Antisense oligodeoxyribonucleotide targeting MIF inhibits propagation of influenza virus (H1N1) in A549 cells. | (118) |
|                             | MIF interacts with influenza virus protein PB1-F2 protein. | (119) |
|                             | MIF is released from necrotic lung epithelial cells infected with influenza virus. | (120) |
| Respiratory syncytial virus | Respiratory syncytial virus infection increases Mif mRNA expression in mouse macrophages and inhibition of MIF with ISO-1 (small molecule inhibitor) inhibits RSV-induced release of TNF, MCP-1 and IL-10. | (121) |
| Dengue virus | MIF inhibits migration of dengue virus-infected macrophages to limit virus spread but is also involved in pathogenesis of dengue virus infection, including an overactive inflammatory cytokine response, viral replication, vascular permeability and leakage. | (122–128) |
| Zika virus | MIF inhibits migration of Zika virus-infected macrophages to limit virus spread; Zika virus blocks NF-κB signaling to reduce MIF expression and its role in inhibiting macrophage migration. | (129) |
| West Nile virus | MIF facilitates West Nile virus neuroinvasion and replication and causes an overactive inflammatory response. | (130–132) |
of the infected cell, with differing implications for the host response to DENV.

DDX3X appears the subject of a complex ‘tug of war’, where its involvement in stress granule formation, or binding to NLRP11, prevents its role in NLRP3 inflammasome activation. These findings highlight that DDX3X plays a pivotal role in the ‘cross-talk’ between various arms of innate immune defense and therefore its role might be expected to alter during the course of a viral infection. Further influencing DDX3Xs role in innate immune defense is the host/virus interplay, which is particularly pertinent given the vast number of viruses that block or hijack DDX3X function during infection (Table 1). It is tempting to speculate that multiple viruses that hijack DDX3X not only utilize its helium activity to service their replication, but in binding to DDX3X may concomitantly influence cell fate decisions, evidence for which is now mounting (56, 90). Thus, rather than capturing snapshots of DDX3X’s function during viral invasion, it should instead be systematically explored at multiple time points during viral infection.

Vimentin

Vimentin is a type III intermediate filament cytoskeletal protein expressed mostly in mesenchymal cells, including cells of the immune system. Vimentin filaments modulate a wide variety of cellular functions, including cytoskeletal stabilization, migration, adhesion, division, organelle homeostasis, signaling, aggresome formation, lipid metabolism and gene regulation. Vimentin has important roles to play in immune responses, including inflammation, wound healing, fibrosis and the host response to infectious pathogens, including viruses (134). Phosphorylated vimentin can also be expressed at the surface of cells, including macrophages and neutrophils and is secreted in response to various cellular processes, including cell activation, apoptosis, senescence and stress (135–138).

Vimentin and NLRP3

Vimentin filaments have been found to play an important role in several sensing pathways, potentially acting as a protein scaffold that stabilizes signaling complexes. Moreover, vimentin has been shown to interact with signaling molecules, including phosphorylated extracellular-regulated kinase 1/2 (pERK1/2) and NOD2, which it binds via the LRR, a protein binding domain shared by multiple NLRs, including NLRP3 (139, 140). Based on this, dos Santos and colleagues investigated whether vimentin had a role to play in NLRP3 inflammasome activation (141). In response to intraperitoneal injection of lipopolysaccharide (LPS) or intratracheal administration of asbestos or bleomycin, measures of acute lung injury (ALI), including histopathology and levels of caspase-1 and IL-1β, were attenuated in Vim−/− mice, compared to wild type (WT) controls.

Similarly, NLRP3 inflammasome activation, measured by caspase-1 activation and release of mature IL-1β, was significantly reduced in primary alveolar macrophages from Vim−/− mice treated with LPS and ATP ex vivo, as well as in human THP-1 macrophages transfected with siRNA against VIM and treated with LPS and asbestos or monosodium urate (MSU) crystals (141). Likewise, mouse immortalized BMDMs treated with the vimentin-binding anti-angiogenic compound withaferin A show significantly reduced NLRP3 activation in response to LPS and the bacterial toxin nigericin (122). Moreover, vimentin was found to co-localize and interact with NLRP3 in THP-1 cells by confocal microscopy, co-immunoprecipitation and using a bio-layer interferometer (141). Similarly, super resolution microscopy has shown NLRP3 to co-localize with filamentous vimentin (122) (Figure 1). Nonetheless, whether intermediate filaments are involved in NLRP3 activation, or whether vimentin acts independently of them, is not yet clear. Vimentin is also present on particles which are converted into short motile intermediate filaments, or ‘squiggles’, the movement of which depends on microtubules (142). In this context, it is interesting that tubulin inhibitors, including colchicine, have been shown to inhibit NLRP3 activation (143, 144). Colchicine is an anti-inflammatory drug that is currently approved for treatment of acute flares of gout and familial Mediterranean fever, as well as off-label for multiple inflammatory and autoimmune conditions (145). More recently, it has been looked at as a potential treatment for SARS-CoV-2 (146).

Vimentin and immunity to viruses

Studies have highlighted a role for vimentin in the entry, replication and release of many different viruses (Table 1). Extracellular/cell surface vimentin has been implicated in the entry of SARS-CoV, SARS-CoV-2, DENV, foot-and-mouth disease virus (FMDV) and human papillomavirus 16 pseudovirions (99, 100, 110, 112, 147). Intracellular vimentin, on the other hand, has been shown to regulate the activity, transport and/or replication of IAV, DENV and HCV (103, 106, 111). Conversely, some viruses target and modify vimentin to aid their replication, including DENV, FMDV and group B human enteroviruses (106, 109, 148). In the case of IAV infection, vimentin appears to be critical for host cell responses, as levels of virus mRNA and protein, along with virus titres, were significantly reduced in infected Vim−/− mouse embryonic fibroblasts (103). Interestingly, these Vim−/− cells also demonstrated impaired endosomal distribution and acidification, leading to the accumulation of virions in late endosomes. It is proposed that this may, in turn, block the release of the viral genome (103). For SARS-CoV-2, surface vimentin appears to be critical for virus entry. Vimentin binds to the SARS-CoV-2 spike protein and facilitates the entry of pseudotyped viruses expressing the spike protein into HEK-
293 and A549 cells expressing ACE2 (100). Specifically, vimentin binds to the receptor binding domain (RBD) of the spike protein, but at a different site to ACE2 (100).

In addition to cytoskeletal rearrangement and intracellular trafficking, vimentin can potentially modulate host cell immune/inflammatory responses to viruses. The role of vimentin in NLRP3 assembly and activation may underlie the observation that Vim−/− mice infected with IAV show decreased mortality and measures of alveolar and lung capillary damage compared to WT animals (149). Viral replication and clearance were not affected by loss of vimentin, suggesting that protection was against the damaging inflammation, rather than viral titres. This is further exemplified by reduced levels of pro-inflammatory cytokines in Vim−/− mice infected with IAV, including IL-1β, TNF, RANTES (regulated upon activation, normal T cell expressed and presumably secreted), MIP2α (macrophage inflammatory protein 2 alpha), monocyte chemoattractant protein-1 (MCP-1/ CCL2), IFN-α and IFN-β (149). This same study also identified three distinct populations of monocyte-derived alveolar macrophages (MoAMs) involved in infiltrating, early and late inflammatory responses to IAV. Compared to WT cells, expression of core pro-inflammatory genes in early phase Vim−/− MoAMs was reduced, while late-stage cells were unaffected by loss of vimentin. Interestingly, 3 distinct clusters of MoAMs were identified in bronchoalveolar lavage fluid from patients with severe SARS-CoV-2 pneumonia, the most inflammatory of which also had the highest expression of VIM (149).

In addition to its role in NLRP3 inflammasome assembly and activation, vimentin has been shown to interact directly with the LRR domain of NOD2 at the plasma membrane of HEK293 cells (140). Inhibition of this interaction with withaferin A induced relocation of NOD2 from the plasma membrane to the cytosol and abrogated NOD2-dependent NF-κB activation and autophagy in response to treatment of cells with muramyl dipeptide (MDP), a component common to all bacteria (140). This is of potential significance to virus infection, as NOD2 is activated by infection with IAV and promotes IRF3-dependent transactivation of IFN-β (150). Moreover, MDP induces the NOD2-dependent recruitment of inflammatory (Ly6Chigh) monocytes to the lungs of IAV infected mice, coupled with increased type I IFN and MCP-1/CCL2. In both Nod2−/− and Cdl2−/− mice, recruitment of Ly6Chigh monocytes was impaired and survival of the animals reduced (151).

Macrophage migration inhibitory factor

Macrophage migration inhibitory factor (MIF) is a pleiotropic pro-inflammatory molecule with multiple proposed roles in immune and non-immune cells. Originally discovered as a lymphokine that inhibits macrophage movement in vitro, MIF is now known to be released by most cells and has chemokine function, able to direct the recruitment of lymphocytes, monocytes and neutrophils to sites of inflammation (152). MIF also regulates the release of other cytokines and chemokines, including TNF, MCP-1, IL-8 and IL-1 family members (122, 153, 154) and regulates p33-dependent apoptosis and transcriptional activity (155). However, MIF is an unusual cytokine, possessing tautomerase and thiol-protein oxidoreductase enzymatic activities, although in vivo targets for these activities have not yet been found (156). Moreover, precisely how MIF, which does not carry an N-terminal signal peptide required for conventional secretion, is released from cells is not clear. Studies have suggested an unconventional pathway, involving the Golgi complex associated protein p115 and proteins of the ATP binding cassette transporter subfamily 1 (ABCA1) (157, 158), as well as release by dying/necrotic cells (159, 160). Moreover, MIF is induced by, and counteracts the effects of, glucocorticoids, steroid hormones that regulate immune cell function and suppress inflammation (161, 162). MIF inhibitors also have steroid-sparing effects (154). A second MIF family member, D-dopachrome tautomerase (D-DT or MIF-2) has also been characterized, showing structural homology to MIF and similar enzymatic activity, with initial work suggesting that there may be some functional redundancy (163, 164). However, while MIF and D-DT appear to share similar pathogenic roles in multiple sclerosis, they seem to have diverging roles in other diseases, including systemic sclerosis (165).

MIF and NLRP3

Studies have demonstrated that Mif−/− mice and their cells secrete less IL-1β and IL-18 in response to infectious organisms than WT controls (166, 167). Moreover, MIF has been shown to drive IL-1β release and disease severity in a mouse model of gout (168). More recently, two studies have highlighted a specific role for MIF in the activation of the NLRP3 inflammasome (122, 169). In one study, inhibition of MIF in macrophages inhibits the release of IL-1β and IL-18 in response to NLRP3-specific stimuli, including the IAV peptide P81-F2 (122). MIF was required for inflammasome activation and the interaction between NLRP3 and vimentin. Moreover, MIF was found to interact directly, or in complex with, NLRP3, suggesting a direct intracellular role for MIF in NLRP3 inflammasome activation/assembly (122) (Figure 1). A second study identified a link between MIF and NLRP3 activation in the response of human monocytes to RNA-containing U1 small nuclear ribonucleoprotein (snRNP) immune complexes (169). Release of MIF by monocytes was increased in response to U1 snRNP immune complexes and concomitant release of IL-1β was inhibited by a small molecule MIF inhibitor, which reduced activation and inhibited the expression of NLRP3 protein and mRNA (169). U1 snRNP immune complexes increased the expression of the cognate MIF receptors CD74 and CD44.

Macrophage migration inhibitory factor

Macrophage migration inhibitory factor (MIF) is a pleiotropic pro-inflammatory molecule with multiple proposed roles in immune and non-immune cells. Originally discovered as a lymphokine that inhibits macrophage movement in vitro, MIF is now known to be released by most cells and has chemokine function, able to direct the recruitment of lymphocytes, monocytes and neutrophils to sites of inflammation (152). MIF also regulates the release of other cytokines and chemokines, including TNF, MCP-1, IL-8 and IL-1 family members (122, 153, 154) and regulates p33-dependent apoptosis and transcriptional activity (155). However, MIF is an unusual cytokine, possessing tautomerase and thiol-protein oxidoreductase enzymatic activities, although in vivo targets for these activities have not yet been found (156). Moreover, precisely how MIF, which does not carry an N-terminal signal peptide required for conventional secretion, is released from cells is not clear. Studies have suggested an unconventional pathway, involving the Golgi complex associated protein p115 and proteins of the ATP binding cassette transporter subfamily 1 (ABCA1) (157, 158), as well as release by dying/necrotic cells (159, 160). Moreover, MIF is induced by, and counteracts the effects of, glucocorticoids, steroid hormones that regulate immune cell function and suppress inflammation (161, 162). MIF inhibitors also have steroid-sparing effects (154). A second MIF family member, D-dopachrome tautomerase (D-DT or MIF-2) has also been characterized, showing structural homology to MIF and similar enzymatic activity, with initial work suggesting that there may be some functional redundancy (163, 164). However, while MIF and D-DT appear to share similar pathogenic roles in multiple sclerosis, they seem to have diverging roles in other diseases, including systemic sclerosis (165).

MIF and NLRP3

Studies have demonstrated that Mif−/− mice and their cells secrete less IL-1β and IL-18 in response to infectious organisms than WT controls (166, 167). Moreover, MIF has been shown to drive IL-1β release and disease severity in a mouse model of gout (168). More recently, two studies have highlighted a specific role for MIF in the activation of the NLRP3 inflammasome (122, 169). In one study, inhibition of MIF in macrophages inhibits the release of IL-1β and IL-18 in response to NLRP3-specific stimuli, including the IAV peptide P81-F2 (122). MIF was required for inflammasome activation and the interaction between NLRP3 and vimentin. Moreover, MIF was found to interact directly, or in complex with, NLRP3, suggesting a direct intracellular role for MIF in NLRP3 inflammasome activation/assembly (122) (Figure 1). A second study identified a link between MIF and NLRP3 activation in the response of human monocytes to RNA-containing U1 small nuclear ribonucleoprotein (snRNP) immune complexes (169). Release of MIF by monocytes was increased in response to U1 snRNP immune complexes and concomitant release of IL-1β was inhibited by a small molecule MIF inhibitor, which reduced activation and inhibited the expression of NLRP3 protein and mRNA (169). U1 snRNP immune complexes increased the expression of the cognate MIF receptors CD74 and CD44.
mouse models of IAV infection, extracellular MIF has been shown to drive NF-κB activation through direct interaction with thioredoxin-interacting protein (TXNIP) (170), which in turn inhibits NF-κB activity. This might be expected to subsequently increase the production of pro-IL-1β, pro-IL-18 and NLRP3, suggesting that MIF inhibitors may abrogate NLRP3 activation through regulation of both NF-κB and NLRP3. However, in our own study, we found no effect of MIF inhibitors on NF-κB activity nor on LPS-induced IL-1β or NLRP3 production (122). Nonetheless, given that MIF is released by necrotic neutrophils and macrophages (159, 160), we can speculate that activation of the NLRP3 inflammasome and subsequent cell death via pyroptosis might drive a positive-feedback loop leading to further activation of the NLRP3 inflammasome.

MIF and immunity to viruses

While MIF has protective roles to play in immunity against pathogens, including *Salmonella typhimurium, Aspergillus fumigatus, Trypanosoma cruzi* and *Klebsiella pneumoniae* (167, 171–173), it has pathological, pro-inflammatory roles in animal models of disease, including systemic lupus erythematosus (SLE), multiple sclerosis (MS) and rheumatoid arthritis (RA) (152). MIF has also been implicated in pathological and inflammatory responses to a number of different human viruses, including RSV (121), Ross River virus (174), DENV (123, 124), WNV (130) and IAV (117) (Table 1). MIF release by mouse macrophages is increased by replicating RSV in vitro and this appears to drive the release of other cytokines including TNF, MCP-1 and IL-10 (121). In the case of DENV, MIF is elevated in infected patients, but there is conflicting data on its correlation with disease severity (125, 126). Nonetheless, inhibition or genetic deletion of MIF has been shown to decrease inflammation and reduce virus replication (123, 175), with one report indicating that increased extracellular MIF might promote DENV replication in vitro, by enhancing autophagic flux in Huh-7 cells (175). Serum levels of MIF are raised in patients infected with West Nile virus and patients with high expression MIF polymorphisms were more likely to develop virus-associated encephalitis (130).

Serum MIF is similarly increased in patients with IAV, has been associated with disease severity and may have utility as a predictor of disease outcome (176, 177). Intracellular levels of MIF are also raised in human lung epithelial cells infected with IAV (118) and intracellular stores of MIF are released from infected cells when infected cells become necrotic (120). In mouse models of IAV infection, *Mif*<sup>−/−</sup> animals have been shown to have reduced lung inflammation, including 10-fold lower levels of IL-1β, reduced viral load and lower mortality (117). Likewise, treatment of infected mice with the MIF inhibitor ISO-1 has been shown to reduce levels of pro-inflammatory cytokine and chemokine mRNA, including IL-1β, in the lungs (178). Conversely, transgenic mice overexpressing MIF in alveolar epithelial cells had more inflammation, higher viral loads and higher mortality (117).

Early studies have also hinted at a pathologic role for MIF in patients infected with SARS-CoV-2. Serum MIF levels were found to be higher in patients with SARS-CoV-2, compared to healthy controls and higher in patients with severe versus moderate disease (114). Similarly, in a study of mechanically ventilated SARS-CoV-2 patients, higher levels of MIF were associated with impaired organ function, increased arterial hypertension and lower 28-day survival (115). In another study in which 65 serum proteins were measured in patients with severe/critical and mild/moderate SARS-CoV-2, along with healthy controls, MIF was the only cytokine raised in both the mild/moderate and severe/critical patients, along with a number of chemokines, growth factors and soluble receptors (116). Interestingly, in this study no difference was observed in MIF levels between the two groups of SARS-CoV-2-infected patients. Levels of IL-18 were significantly higher in critical/hospitalized patients, compared to healthy controls, while IL-1β was not detected in enough patients for analysis (116).

To what extent, if any, MIF regulates host-virus responses through modulation of the NLRP3 inflammasome is not yet understood, although the fact that inhibition or deletion of MIF is almost universally anti-inflammatory, commonly reducing the release of IL-1β, would certainly point to it as a likely pathway of significance. Likewise, the fact that inhibiting MIF abrogates IL-1β and IL-18 release in response to the IAV peptide PB1-F2 (122), further points to regulation of NLRP3 being key to MIFs role in virus-induced hyperinflammation. Thus, targeting MIF, as well as DDX3X and vimentin, potentially offers a novel way of inhibiting NLRP3 clinically.

Clinical efforts to suppress NLRP3-mediated inflammation

Given NLRP3-mediated inflammation and cytokine storm are associated with disease severity in IAV and SARS-CoV-2 infection (179), suppressing NLRP3 inflammasome hyperactivation and cytokine storm may alleviate acute respiratory distress syndrome (ARDS). As proof-of-principal, MCC950 treatment in a human ACE2 transgenic mouse model (hACE2-tg) quenched levels of inflammatory cytokines and alleviated lung pathology compared to phosphate-buffered saline (PBS)-treated mice (180). Young mice intraperitoneally treated with MCC950 three days post IAV virus infection showed reduced NLRP3 and activated caspase-1, regained weight 8–9 days post-infection and improved survival compared to their PBS-treated IAV-infected counterparts.
However, both cohorts exhibited similar lung pathology, suggesting the NLRP3 inflammasome plays a role in recovery from IAV infection (181). A similar study in MCC950-treated IAV-infected adult mice showed that those treated 7 days post-infection had improved survival, however enhanced lethality was observed in mice treated sooner post-infection (182). Therefore, the timing of treatment administration should be considered. MCC950 has been used in phase II clinical trials in patients with RA, in which the activation of the NLRP3 inflammasome plays a role (183), however MCC950 caused liver toxicity (184), sparking the pursuit of NLRP3 inhibitors with enhanced pharmacokinetic properties. To our knowledge only the NLRP3 inhibitor DFV890 (Novartis Pharmaceuticals NCT04382053) has completed phase II clinical trials for efficacy against SARS-CoV-2-induced pneumonia, however DFV890 treatment did not influence disease severity, nor reduce the inflammatory marker serum C-reactive protein. Nonetheless, pharmacological inhibitors of the NLRP3 inflammasome are being avidly pursued, although none are currently FDA-approved.

Quenching the hyperinflammatory response via NLRP3 inflammasome inhibitors may be advantageous compared to glucocorticoids, such as dexamethasone, to treat SARS-CoV-2 and IAV infections. While both approaches reduce inflammation, glucocorticoids negatively impact the type I IFN response, which is necessary to restrict viral replication in infected cells and limit viral spread to non-infected cells (185). For this reason, early-stage treatment of glucocorticoids, when the viral load is high, is not recommended. Corticosteroids are also immunosuppressive and have been linked to a rise in life-threatening infections (186–188) and hyperglycemia (189).

**Modulating the NLRP3 modulators**

Because it is linked to so many different pathologies, the NLRP3 inflammasome has been a *bona fide* target for drug development for several years, with multiple companies running programs to develop drugs that target this critical inflammatory pathway. Thus, modulators of NLRP3 inflammasome activation, such as DDX3X, vimentin and MIF, may themselves be viable targets for developing agents that block NLRP3-mediated inflammation.

**DDX3X**

With its role in NLRP3 inflammasome activation and its conflicting roles in viral replication and suppression, DDX3X is a potentially interesting therapeutic target. For viruses, such as SARS-CoV-2, which utilize DDX3X to service their replication and where infection can progress to life-threatening ARDS, the strategic targeting of DDX3X may combat both viral load and virus-induced inflammation. Intriguingly however, while the DDX3X catalytic inhibitor RK-33 can limit SARS-CoV-2 replication in Vero E6 and Calu-3 cells (70), it did not prevent the cleavage of pro-caspase-1 into the mature p20 subunit following the stimulation of BMDCs with LPS and nigericin (55). Therefore, DDX3X appears to play a protein scaffolding, rather than catalytic role in NLRP3 inflammasome activation. The detailed characterization of the DDX3X-NLRP3 interaction interface may therefore reveal opportunities to disrupt NLRP3 inflammasome activation. Likewise, post-translational modifiers of DDX3X may also prove viable targets. AKT is proposed to phosphorylate DDX3X and in doing so disrupt the DDX3X-NLRP3 interaction (190). The determination of the DDX3X AKT-phosphorylation site/s would validate these results and potentially highlight a unique DDX3X-targeting site. Likewise, other post-translational modifiers of DDX3X, including tripartite motif protein 25 (TRIM25) (39) and TANK binding kinase 1 (TBK1) (43), may influence NLRP3 inflammasome activation but these remain to be explored.

**Vimentin**

Given its broad roles in both inflammatory and host-virus responses, vimentin is an attractive target for the development of novel therapeutics. Moreover, because intracellular and extracellular/surface vimentin appear to contribute differently to these roles, the possibility of targeting specific effects is of potential interest. In particular, extracellular vimentin, which can be targeted with anti-vimentin antibodies, has potential for the development of drugs that inhibit virus entry into cells. Targeting of surface vimentin has been shown to inhibit the uptake of SARS-CoV virus-like particles and spike protein by permissive Vero cells (99). Alternatively, small molecule inhibitors, which can enter the cell and access the cytosol, have the potential to disrupt intermediate filament networks, interfering with the intracellular trafficking of viruses, as well as interactions between vimentin and immune signaling pathways, including NLRP3. Withaferin A, a natural withanolide, for example, has been shown to inhibit NLRP3 activation in mouse macrophages (122), as well interfering with the vimentin-NOD interaction. Future strategies to target these specific interactions could lead to the discovery of potent NLRP3-inhibiting drugs.

**MIF**

Similar to vimentin, MIF has both intracellular and extracellular functions that are potentially relevant to its role in virus entry and replication, as well as in NLRP3 activation. In a mouse model of IAV infection, treatment of mice with an anti-MIF neutralizing antibody significantly increased survival (117), although whether this is due to effects on NLRP3 activation is...
unclear. However, treatment of mouse macrophages with the small molecule MIF inhibitor COR123625, has been shown to inhibit IL-1β and IL-18 release in response to the IAV peptide PB1-F2 (122), which is known to activate NLRP3 (34). Of significance, a clinical trial is currently underway to test the efficacy of ibudilast (MN-166) in patients infected with SARS-CoV-2 and at risk of developing ARDS (NCT04429555). Ibudilast is a phosphodiesterase inhibitor approved for the treatment of asthma in Japan that has also been shown to also inhibit MIF tautomerase activity (191). Given that MIF has been shown to interact, either directly or in a complex, with NLRP3 (122), future studies to identify the critical residue(s) on the MIF molecule for this interaction could lead to highly specific and potent NLRP3-targeting compounds.

Conclusions

In the early stages of infection, viral replication is restricted by the type I IFN response and can be aided by treatment with antiviral inhibitors that block viral replication. However, severe viral infections, caused for example by SARS-CoV-2 and IAV, can cause excessive inflammation and develop into life-threatening ARDS. ARDS is currently managed by supportive treatment, such as mechanical ventilation to improve oxygen levels in the blood, however the root cause, hyperinflammation, is typically not pharmacologically treated. In patients with severe SARS-CoV-2, generically quenching the hyperinflammatory response using corticosteroids has shown benefit (192), but may have serious side-effects (193). Alternatively, treating NLRP3-mediated inflammation with specific inhibitors has also shown promise in both SARS-CoV-2- and IAV-infected mouse models and are being pursued by pharmacological companies with great enthusiasm. The identification of new NLRP3 components and accessory molecules, such as DDX3X, vimentin and MIF, which themselves have other regulatory roles in antiviral immunity, reveal the growing complexity of NLRP3 inflammasome regulation. Importantly, it also reveals new opportunities for the development of novel therapeutic strategies to suppress NLRP3-induced inflammation with the potential to reduce disease severity and improve patient outcomes.

Author contributions

JH and NB: manuscript preparation, including original draft preparation, reviewing, editing and finalizing. All authors contributed to the article and approved the submitted version.

Funding

This research was funded by the National Health and Medical Research Council (NHMRC) APP1157053.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res (2020) 176:104742. doi: 10.1016/j.antiviral.2020.104742.
2. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell (2020) 181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052.
3. Jaimes JA, Millet JK, Whitaker GR. Proteolytic cleavage of the SARS-CoV-2 spike protein and the role of the novel S1/S2 site. Science (2020) 236:101212. doi: 10.1016/j.sci.2020.101212.
4. Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin (2020) 41(9):1141-9. doi: 10.1038/s41401-020-0485-4.
5. Clausen TM, Sandoval DR, Spliid CB, Pihl J, Perrett HR, Painter CD, et al. SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2. Cell (2020) 183(4):1043–57.e15. doi: 10.1016/j.cell.2020.09.033.
6. Wang K, Chen W, Zhang Z, Deng Y, Lian JQ, Du P, et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct Target Ther (2020) 5(1):283. doi: 10.1038/s41392-020-00426-x.
7. Cantuti-Castelvetri L, Ojha R, Pedro LD, Djanattian M, Fraun J, Kuivanen S, et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science (2020) 370(6518):856–60. doi: 10.1126/science.abc2985.
8. Amraei R, Yin W, Napoleone MA, Suder EL, Berrigan J, Zhao Q, et al. CD209/L-SIGN and CD209/DC-SIGN act as receptors for SARS-CoV-2. ACS Cent Sci (2021) 7(7):1156–65. doi: 10.1021/acscentsci.0c01537.
9. Yang ZY, Huang Y, Ganesh L, Leong K, Kong WP, Schwartz O, et al. pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol (2004) 78(11):5642–50. doi: 10.1128/JVI.78.11.5642-5650.2004.
Harris and Borg 10.3389/fimmu.2022.987453

10. Jeffers SA, Tuell SM, Gilmore-Ross L, Hemimla EM, Achenbach JF, Babcock GJ, et al. CD200R (LSECIN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U.S.A. (2004) 101(44):15748–53. doi: 10.1073/pnas.0403812101

11. Lempp FA, Soriaga LB, Montiel-Ruiz M, Benigni F, Noack J, Park YJ, et al. LTB4 enhances SARS-CoV-2 infection and inflammation. Nat Commun (2021) 12(1):508. doi: 10.1038/s41467-020-19280-8

12. Pan P, Shen M, Yu Z, Ge W, Chen K, Tian M, et al. SARS-CoV-2 nsp15 promotes NLRP3 inflammasome activation by inducing hyperinflammation. Nat Commun (2021) 12(3):4664. doi: 10.1038/s41467-020-19280-8

13. Shih JW, Tsai TY, Hao CH, Wu LK, Tsai TY, Kuo CY, Li HK, Wu YH. Critical roles of RNA helicase DDX3X in dDX3X and its interactions with eIF4E inhibitory protein. Oncogene (2008) 27(5):700–14. doi: 10.1038/onc.2007.388

14. Venkataramanan S, Gadek M, Calviello L, Wilkins K, Floor SN. DDX3X and DDX3Y are redundant in protein synthesis. RNA (2021) 27(12):1577–88. doi: 10.1261/rna.079262.121
66. Eason A, Gould P, Marsh A. Inventor; use of DDX3X inhibitors for the treatment of pneumovirus infections. Patent PCT/GB2015/050724. (2012).

67. Yang SNT, Atkinson SC, Audley MD, Heathon SM, Jana DA, Borg NA. RK-33 is a broad-spectrum antiviral agent that targets DEAD-box RNA helicase DDX3X. Cell (2020) 9(1):170. doi: 10.1016/j.cell.201010170

68. Khudha S, Vangeloof AD, Zhang C, Siddavatam P, Heathon NS, Wang L, et al. A physical interaction network of dengue virus and human proteins. Mol Cell Proteomics (2010) 11(12):M110.012187. doi: 10.1074/mcp.M110.012187

69. Kumar R, Singh N, Abdin MZ, Patel AH, Medigeshi GR. Dengue virus capsid interacts with DDX3X-a potential mechanism for suppression of antiviral functions in dengue infection. Front Cell Infect Microbiol (2017) 7:542. doi: 10.3389/fcimb.2017.00542

70. Brai A, Fari R, Tinitori C, Zamperini C, Bugli F, Sanguinetti M, et al. Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents. Proc Natl Acad Sci USA (2016) 113(19):5888–93. doi: 10.1073/pnas.1522987113

71. Brai A, Boscotti A, Monti M, Marchi S, Vicenti I, Saladino F, et al. Exploring the implication of DDX3X in DENV infection: Discovery of the first-in-Class DDX3X fluorescent inhibitor. ACS Med Chem Lett (2020) 11(5):956–62. doi: 10.1021/acsmedchemlett.9b00681

72. Li G, Feng T, Pan W, Shi X, Daj. DEAD-box RNA helicase DDX3X inhibits DENV replication via regulating type one interferon pathway. Biochem Biophys Res Commun (2015) 456(1):327–47. doi: 10.1016/j.bbrc.2014.11.080

73. Nelson C, Mrozowich T, Gemmill DL, Park SM, Patel TR. Human DDX3X unwindss Japanese encephalitis and zika viral 5’ terminal regions. Int J Mol Sci (2021) 22(S1):413. doi: 10.3390/ijms22010413

74. Brai A, Martelli F, Riva V, Garbelbi A, Fari R, Zamperini C, et al. DDX3X helicase inhibitors as a new strategy to fight the West Nile virus infection. J Med Chem (2019) 62(5):2333–47. doi: 10.1021/acs.jmedchem.8b01403

75. Li G, Lee LI, Li PP, Wang Y, Dai JI, Sun MX, et al. Cellular DEAD FX 3 regulates Japanese encephalitis virus replication by interacting with viral un-translated regions. Virology (2014) 449:70–81. doi: 10.1016/j.virol.2013.11.008

76. Wang H, Kim S, Ryu WS. DDX3X DEAD-box RNA helicase inhibits hepatitis B virus reverse transcription in incorporation into nucleocapsids. J Virol (2009) 83(15):5185–24. doi: 10.1128/JVI.00109-09

77. Ko C, Lee S, Windisch MP, Ryu WS. DDX3 DEAD-box RNA helicase is a host factor that restricts hepatitis B virus replication at the transcriptional level. J Virol (2008) 82(23):13698–9. doi: 10.1128/JVI.01517-07

78. Li Q, Pene V, Krishnamurthy S, Sha H, Liang T. Hepatitis C virus infection activates an innate pathway involving IKG-alpha in lipogenesis and viral assembly. Nat Med (2013) 19(6):722–9. doi: 10.1038/nm.3190

79. Pene V, Li Q, Sodirocks C, Hou CS, Liang T. Dynamic interaction of stress granules, DDX3X, and IKG-alpha mediates multiple functions in hepatitis C virus infection. J Virol (2015) 89(3):1564–77. doi: 10.1128/JVI.01517-14

80. Arumi Y, Kuroki M, Abe K, Dansako H, Ikeda M, Wakita T, et al. DDX3 DEAD-box RNA helicase is required for hepatitis C virus RNA replication. J Virol (2007) 81(13):12884–8. doi: 10.1128/JVI.01517-07

81. Randall G, Panis M, Cooper JD, Tellinghuisen TL, Sukhodolets KE, Pfeffer S, et al. Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci U.S.A. (2007) 104(31):12884–9. doi: 10.1073/pnas.0704894010

82. Angus GA, Dalrymple D, Boulant S, McGivern DR, Clayton RF, Scott MJ, et al. Requirement of cellular DDX3 for hepatitis C virus replication is unrelated to its interaction with the viral core protein. J Gen Virol (2010) 91(Pt 1):122–32. doi: 10.1128/JVI.01590-09

83. Mamiya N, Wororm JH. Hepatitis C virus core protein binds to a DEAD-box RNA helicase. J Biol Chem (1999) 274(22):15751–6. doi: 10.1074/jbc.274.22.15751

84. Ohshumi H, Ikeda M, Matsumoto M, Watanabe A, Takachi H, Akira S, et al. Hepatitis C virus core protein abrogates the DDX3X function that enhances IPS-1-mediated IFN-beta induction. PLoS One (2010) 5(12):e14258. doi: 10.1371/journal.pone.0014258

85. Oshikawa A, Ando AY, Shibata H. Human alphavirus core protein interacts with a DEAD-box RNA helicase. Virology (1999) 257(2):330–40. doi: 10.1006/viro.1999.9659

86. Sat0 S, Fukasawa M, Yamakawa Y, Natsume T, Suzuki T, Shoji I, et al. Proteomic profiling of lipid droplet proteins in hepatoma cell lines expressing hepatitis C virus core protein. J Biochem (2006) 139(5):521–30. doi: 10.1262/jbc.M109004104

87. Fernandez-Ortega C, Ramirez A, Casillas D, Paneque T, Ubieta R, Dubed M, et al. Identification of vimentin as a potential therapeutic target against HIV infection. Virusx (2016) 8(6):14. doi: 10.1186/s40098-016-0234-7

88. Yu YT, Chen SC, Chen JY, Lai CT, Tsay YG, Chang SC, et al. Surface vimentin is critical for the cell entry of SARS-CoV. J BioMed Sci (2016) 23:14. doi: 10.1186/s12929-016-0224-7
with foot-and-Mouth disease virus nonstructural protein 3A and negatively
virus core protein and the hepatitis c virus production in cultured cells.

Frontiers in Immunology

J VI.01393-19

fi

(2002) 76(4):1839

membranes and vimentin

Rodriguez D. Endoplasmic reticulum-golgi intermediate compartment

Harris and Borg 10.3389/

(2013) 100(3):673

subcellular level for host targets against in

mice.

JCI Insight

et al. Macrophage migration inhibitory factor (MIF) plasma concentration in

COVID-19 pneumonia.

et al. Elevated levels of macrophage migration inhibitory factor in the plasma

SARS-CoV-2 spike proteins reveals selective colocalization at primary cilia.

Poyatos A, Merino A, et al. Cell surface detection of vimentin, ACE2 and SARS-

entry into human endothelial cells.

et al. Extracellular vimentin is an attachment factor that facilitates SARS-CoV-

2 infection of lung epithelial cells rendered necrotic by influenza virus infection.

J Virol (2002) 76(18):9298–306. doi:10.1128/jvi.76.18.9298-9306.2002

121. de Souza GF, Muraro SP, Santos LD, Monteiro APT, da Silva AG, de Souza AP, et al. Macrophage migration inhibitory factor (MIF) controls cytokine release during respiratory syncytial virus infection in macaques. Inflammation Res (2019) 68(6):481–91. doi:10.1007/s10011-019-01233-z

122. Lang T, Lee JPW, Elgass K, Pinar AA, Tate MD, Atkin EH, et al. Macrophage migration inhibitory factor is required for NLRP3 inflammasome activation.

Assuncao-Miranda I, Amaral FA, Bozza FA, Fagundes CT, Sousa LP, Souza DG, et al. Contribution of macrophage migration inhibitory factor to the pathogenesis of dengue virus infection. FEBS Lett (2010) 524(1):218–28. doi:10.1016/j.febslet.2009.13-15

124. Chuan YC, Chen HR, Yeh TM. Pathogenic roles of macrophage migration inhibitory factor during dengue virus infection. Mediators Inflammation (2015) 2015:547904. doi:10.1155/2015/547904

125. Chen LC, Lei HY, Liu GC, Shieh SC, Chen SH, Liu HS, et al. Correlation of serum levels of macrophage migration inhibitory factor with disease severity and clinical outcome in dengue patients. Am J Trop Med Hyg (2006) 74(1):142–7. doi:10.4269/ajtmh.2006.74.142

126. Oliveira R, Cordeiro MT, Moura P, Baptista Filho PN, Braga-Neto UM, Marques ETAI, et al. Serum cytokine/chemokine profiles in patients with dengue fever (DF) and dengue hemorrhagic fever (DHF) by using protein array. J Clin Virol (2017) 89:39–45. doi:10.1016/j.jcv.2017.02.007

127. Chen HR, Chuan YC, Lin YS, Liu HS, Liu CC, Perng GC, et al. Dengue virus nonstructural protein 1 induces vascular leakage through macrophage migration inhibitory factor and autophagy. PLoS Negl Trop Dis (2016) 10(7):e0004828. doi:10.1371/journal.pntd.0004828

128. Chuan YC, Lei HY, Liu HS, Lin YS, Fu TF, Yeh TM. Macrophage migration inhibitory factor induces dengue virus infection increases vascular permeability. Cytokine (2011) 54(2):222–31. doi:10.1016/j.cyto.2011.03.013

129. Lang J, Cheng Y, Rolfe A, Hammad C, Vera D, Kyle K, et al. An HPSC-derived tissue-resident macrophage model reveals differential responses of macrophages to ZIKV and DENV infection. Stem Cell Rep (2018) 11(2):348–62. doi:10.1016/j.scr.2018.06.006

130. Das R, Loughran K, Murchison C, Qian F, Leng L, Song Y, et al. Association between high expression macrophage migration inhibitory factor (MIF) alleles and West Nile virus encephalitis. Cytokine (2016) 78:51–4. doi:10.1016/j.cyto.2015.11.021

131. Arjona A, Foeldner HG, Town T, Leng L, McDonald C, Wang T, et al. Abrogation of macrophage migration inhibitory factor decreases West Nile virus lethality by limiting viral neuroinvasion. J Clin Invest (2007) 117(10):3059–66. doi:10.1172/JCI32218

132. Constant O, Barthelmey J, Nagy A, Salinas S, Simonin Y. West Nile Virus Neuroinfection in Humans: Peripheral Biomarkers of Neuroinflammation and Neuronal Damage. Viruses (2012) 4(4):756. doi:10.3390/v4040756

133. Ruggeri A, Dazert E, Metz P, Hofmann S, Bergeest JP, Simpson KW, et al. Dynamic oscillation of translation and stress granule formation mark the cellular response to virus infection. Cell Host Microbe (2012) 12(1):71–85. doi:10.1016/j.chom.2012.05.013

134. Ramos I, Stamatakis K, Oeste CL, Perez-Sala D. Vimentin as a multifaceted player and potential therapeutic target in viral infections. Int J Mol Sci (2020) 21(13):4675. doi:10.3390/ijms21134675

135. Frescas D, Roux CM, Aygun-Sunar S, Gleiberman AS, Krasnov P, Bergeest JP, Simpson KW, et al. Vimentin binds heparin and prevents oxidative activation of human neutrophils. J Leukoc Biol (2006) 80(1):69–74. doi:10.1128/JLB.P09-05

136. Stevens C, Henderson P, Nimmo ER, Soares DC, Dogan B, Simpson KW, et al. Alpha1-antitrypsin binds hemin and prevents oxidative activation of human neutrophils putative pathophysiologic significance. J Leukoc Biol (2017) 104(1):1127–41. doi:10.1189/jlb.A3013-124R

137. Janciauskiene S, Tumpara S, Wiese M, Wrenger S, Vijayan V, Gueler F, et al. Alpha1-antitrypsin binds hemin and prevents oxidative activation of human neutrophils. J Leukoc Biol (2006) 80(1):69–74. doi:10.1128/JLB.P09-05

138. Mor-Vaknin N, Puntarierci A, Sitwala K, Markowitz DM. Vimentin is secreted by activated macrophages. Nat Cell Biol (2003) 5(1):59–63. doi:10.1038/ncb898

139. Perlman S, Iyer L, Liu H, Haggblom N, Ben-Yakov K, Shaked M, Seger R, et al. Vimentin binding to phosphorylated erk sterically hinders enzymatic dephosphorylation of the kinase. J Mol Biol (2006) 364(5):938–44. doi:10.1016/j.jmb.2006.09.056

140. Stevens C, Henderson P, Nimmo ER, Soares DC, Dogan B, Simpson KW, et al. Cell surface detection of vimentin, ACE2 and SARS-CoV-2 spike proteins is an attachment factor that prevents oxidative activation of human neutrophils. J Leukoc Biol (2020) 107(4):4127–41. doi:10.1189/jlb.3A3013-124R

141. dos Santos G, Rogel MR, Baker MA, Troken BJ, Urich D, Morales-Nebreda L, et al. Vimentin regulates activation of the NLRP3 inflammasome. Nat Commun (2015) 6:6574. doi:10.1038/ncomms5754
MIF: New tricks for an old cytokine.

Fernandez Sainz I, et al. Foot-and-mouth disease virus modulates cellular vimentin

Harris and Borg 10.3389/fimmu.2022.978453

15

Induced NOD2-dependent Ly6C(high) monocyte recruitment to the lungs and for virus survival.

Frontiers in Immunology frontiersin.org

80. doi:10.1038/ni.1782

152. Chakraborty D, Bhattacharyya M, Deshmukh S, et al. Analysis of serum macrophage migration inhibitory factor and d-dopachrome tautomerasce in sars-cov-2 infected patients.

107. coinoume E, idebiyi T, eddine N, Hamadi M, et a.l. Serum level of macrophage migration inhibitory factor in psoriasis patients.

148. Gladue DP, O'Donnell V, Baker-Branstetter R, Holinka LG, Pacheco JM, 150. Sabbah A, Chang TH, Harnack R, Frohlich V, Tominaga K, Dube PH, et al. Macrophage migration inhibitory factor-induced autophagy.

145. Liantinioti G, Argyris AA, Protogerou AD, Vlachoyiannopoulos P. The role of colchicine in the treatment of autoimmune diseases. Curr Pharm Des (2018) 24:6-90. doi: 10.2174/1381612824661801096568

146. Bonaventura A, Vecchie A, Dagna L, Targanelli F, Abbate A, Dentali F. Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperrheumatogenicity.

142. Prahlad V, Yoon M, Moir RD, Vale RD, Goldman RD. Rapid movements of the ammasome: a review of the role of colchicine in the treatment of autoimmune diseases.

139. Fingerle-Rowson G, et al. Critical role for macrophage migration inhibitory factor in Ross river virus-induced arthritis and myositis.

155:28

143. MIF as a glucocorticoid-induced modulator of cytokine production.

161. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, Bacher M, et al. Analysis of innate immune antiviral responses by Nod2. J Nat Immunol (2009) 10:1073-80. doi:10.1038/nj.2009.782

151. Coulombe F, Fiola S, Akira S, Cormor C, Gosselin T. Muramyloid dipeptidase induces NOD2-dependent Ly6c(high) monocyte recruitment to the lungs and protects against influenza virus infection. PloS One (2012) 7(5):e36734. doi: 10.1371/journal.pone.0036732

147. Yang J, Zou L, Yang Y, Yuan J, Hu Z, Liu H, et al. Supercritical vimentin mediates DENV-2 infection of vascular endothelial cells. Sci Rep (2016) 6:38372. doi: 10.1038/srep38372

148. Glade DP, O’Donnell V, Baker-Branstetter R, Holinka LG, Pacheco JM, Fernandez Sainz I, et al. Foot-and-mouth disease virus modulates cellular vimentin for virus survival. J Virol (2013) 87(12):6794–803. doi:10.1128/TVI.00448-13

149. Koch CM, Anekalra KR, Hu Y, S, Davis JM, Cesielski M, Gadgil G, et al. Influenza-virus-induced recruitment of reoviral macropores during the early inflammatory phase drives lung injury and lethality. bioRxiv (2022) 2020.06.08.141309. doi: 10.1038/s41556-020-00643-3

150. Sabbah A, Chang TH, Harnack R, Frohlich V, Tominaga K, Dube PH, et al. Activation of innate immune antiviral responses by Nod2. J Nat Immunol (2009) 10:1073-80. doi:10.1038/nj.2009.782

144. MIF, a controversial cytokine: a review of its role in rheumatoid arthritis.

141. MIF: New tricks for an old cytokine.

145. Liantinioti G, Argyris AA, Protogerou AD, Vlachoyiannopoulos P. The role of colchicine in the treatment of autoimmune diseases. Curr Pharm Des (2018) 24:6-90. doi: 10.2174/1381612824661801096568

146. Bonaventura A, Vecchie A, Dagna L, Targanelli F, Abbate A, Dentali F. Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperrheumatogenicity.
182. Tate MD, Ong JDH, Dowling JK, McAuley AB, Latz E, et al. Reassessing the role of the NLRP3 inflammasome during pathogenic influenza virus infection via temporal inhibition. Sci Rep (2016) 6:27912. doi: 10.1038/srep27912

183. Guo C, Fu R, Wang S, Huang Y, Li X, Zhou M, et al. NLRP3 inflammasome activation contributes to the pathogenesis of rheumatoid arthritis. Clin Exp Immunol (2018) 194(2):231–43. doi: 10.1111/cei.13167

184. Mullard A. NLRP3 inhibitors stoke anti-inflammatory ambitions. Nat Rev Drug Discovery (2019) 18(6):405–7. doi: 10.1038/d41573-019-00086-9

185. Park A, Iwasaki A. Type I and type III interferons - induction, signaling, evasion, and application to combat COVID-19. Cell Host Microbe (2020) 27 (6):870–8. doi: 10.1016/j.chom.2020.05.008

186. Reyes LF, Rodriguez A, Bustidas A, Parra-Tanoux D, Fuentes YV, Garcia-Gallo E, et al. Dexamethasone as risk factor for ICU-acquired respiratory tract infections in severe COVID-19. J Crit Care (2022) 69:154014. doi: 10.1016/j.jcrc.2022.154014

187. Rothe K, Lahmer T, Rasch S, Schneider J, Spinner CD, Wallnofer F, et al. Dexamethasone therapy and rates of secondary pulmonary and bloodstream infections in critically ill COVID-19 patients. Multidiscip Respir Med (2021) 16 (1):793. doi: 10.4081/mrm.2021.793

188. Xing X, Hu S, Chen M, Zhan F, Liu H, Chen Z, et al. Severe acute respiratory infection risk following glucocorticosteroid treatment in uncomplicated influenza-like illness resulting from pH1N1 influenza infection: a case control study. BMC Infect Dis (2019) 19(1):1080. doi: 10.1186/s12879-019-4669-9

189. Larsson H, Ahren B. Insulin resistant subjects lack islet adaptation to short-term dexamethasone-induced reduction in insulin sensitivity. Diabetologia (1999) 42(8):936–43. doi: 10.1007/s001250051251

190. Guo X, Chen S, Yu W, Chi Z, Wang Z, Xu T, et al. AKT controls NLRP3 inflammasome activation by inducing DDX3X phosphorylation. FEBS Lett (2021) 595(19):2447–62. doi: 10.1002/1873-3468.14175

191. Cho Y, Crichlow GV, Vermeire JJ, Leng L, Du X, Hodson ME, et al. Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. Proc Natl Acad Sci U.S.A. (2010) 107(25):11313–8. doi: 10.1073/ pnas.1002716107

192. Martinez-Guerra BA, Gonzalez-Lara MF, Roman-Montes CM, Tamar-Torres KM, Dardon-Fierro FE, Rajme-Lopez S, et al. Outcomes of patients with severe and critical COVID-19 treated with dexamethasone: a prospective cohort study. Emerg Microbes Infect (2022) 11(1):50–9. doi: 10.1080/ 22221751.2021.2011619

193. Tang C, Wang Y, Lv H, Gnan Z, Gu J. Caution against corticosteroid-based COVID-19 treatment. Lancet (2020) 395(10239):1759–60. doi: 10.1016/S0140- 6736(20)30749-2